Nature Communications (Sep 2023)
Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas
- Grayson A. Herrgott,
- James M. Snyder,
- Ruicong She,
- Tathiane M. Malta,
- Thais S. Sabedot,
- Ian Y. Lee,
- Jacob Pawloski,
- Guilherme G. Podolsky-Gondim,
- Karam P. Asmaro,
- Jiaqi Zhang,
- Cara E. Cannella,
- Kevin Nelson,
- Bartow Thomas,
- Ana C. deCarvalho,
- Laura A. Hasselbach,
- Kelly M. Tundo,
- Rehnuma Newaz,
- Andrea Transou,
- Natalia Morosini,
- Victor Francisco,
- Laila M. Poisson,
- Dhananjay Chitale,
- Abir Mukherjee,
- Maritza S. Mosella,
- Adam M. Robin,
- Tobias Walbert,
- Mark Rosenblum,
- Tom Mikkelsen,
- Steven Kalkanis,
- Daniela P. C. Tirapelli,
- Daniel J. Weisenberger,
- Carlos G. Carlotti,
- Jack Rock,
- Ana Valeria Castro,
- Houtan Noushmehr
Affiliations
- Grayson A. Herrgott
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- James M. Snyder
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Ruicong She
- Department of Public Health, Biostatistics, Henry Ford Health
- Tathiane M. Malta
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Thais S. Sabedot
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Ian Y. Lee
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Jacob Pawloski
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Guilherme G. Podolsky-Gondim
- Department of Neurosurgery, Ribeirao Preto Medical School, University of Sao Paulo
- Karam P. Asmaro
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Jiaqi Zhang
- Department of Public Health, Biostatistics, Henry Ford Health
- Cara E. Cannella
- Department of Public Health, Biostatistics, Henry Ford Health
- Kevin Nelson
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Bartow Thomas
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Ana C. deCarvalho
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Laura A. Hasselbach
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Kelly M. Tundo
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Rehnuma Newaz
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Andrea Transou
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Natalia Morosini
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Victor Francisco
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Laila M. Poisson
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Dhananjay Chitale
- Department of Pathology, Henry Ford Health
- Abir Mukherjee
- Department of Pathology, Henry Ford Health
- Maritza S. Mosella
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Adam M. Robin
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Tobias Walbert
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Mark Rosenblum
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Tom Mikkelsen
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Steven Kalkanis
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Daniela P. C. Tirapelli
- Department of Neurosurgery, Ribeirao Preto Medical School, University of Sao Paulo
- Daniel J. Weisenberger
- Department of Biochemistry and Molecular Medicine, Keck School of Medicine, University of Southern California
- Carlos G. Carlotti
- Department of Neurosurgery, Ribeirao Preto Medical School, University of Sao Paulo
- Jack Rock
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Ana Valeria Castro
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- Houtan Noushmehr
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
- DOI
- https://doi.org/10.1038/s41467-023-41434-z
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 19
Abstract
Abstract Recurrence of meningiomas is unpredictable by current invasive methods based on surgically removed specimens. Identification of patients likely to recur using noninvasive approaches could inform treatment strategy, whether intervention or monitoring. In this study, we analyze the DNA methylation levels in blood (serum and plasma) and tissue samples from 155 meningioma patients, compared to other central nervous system tumor and non-tumor entities. We discover DNA methylation markers unique to meningiomas and use artificial intelligence to create accurate and universal models for identifying and predicting meningioma recurrence, using either blood or tissue samples. Here we show that liquid biopsy is a potential noninvasive and reliable tool for diagnosing and predicting outcomes in meningioma patients. This approach can improve personalized management strategies for these patients.
